Currently there are now 29 states that have approved legalized medical cannabis of which 23 million potential patients qualify for some sort of legal cannabis nationwide. The states listed below are the states that can sell the Novus MedPlan:

Management Discussion & Analysis For 2017

As we head into 2017, with a new President, legal cannabis states that have revised laws, and new states that approved cannabis, is a milestone for the industry. We continue to expand the availability of the Novus MedPlan in additional legal cannabis states. The process is arduous, dealing with each State Department that regulates insurance laws, cannabis laws, securities laws and fiduciary requirement laws, making it a tedious and lengthy process.

Being the first to bring health coverage to the legal cannabis segment gives Novus a competitive advantage over other insurance companies. Since legal cannabis is not federally approved, the trepidation of competing insurance entities getting into cannabis could result in a loss of their lucrative Medicare and Medicaid contracts. Novus’ objective is to be compliant on a state level and since we never take possession of the plant we don’t have any risk of state line issues, brought by evidence of a our legal opinion written by the firm Vicente Sederberg the leading cannabis law firm in the country.

The barrier of entry aside from insurance compliance is engaging with cannabis cultivators, manufacturers and dispensaries that we call our “Provider Network” or “Provider(s)”. These Provider(s) are typically early stage companies and the due diligence to determine their criteria of Provider financial validity is cumbersome and getting them to gain trust in corporate America is burdensome, but Novus is and has accomplished this undertaking.

As new and existing legal cannabis states struggle with cannabis rules and regulations, some states struggle with developing markets, but it has been our determination to continue to file with states prior to their markets developing. With cash on hand, no debt or toxic financing and extremely low overhead, Novus’ intrinsic value currently comes from our infrastructure expansion in legal cannabis states and diversified insurance lines.

We have overcome impediments in 2016 by stabilizing depository relationships with banking entities. Solving complexities of Internet companies not allowing our digital marketing to be placed on ad exchanges, resulting of bringing our advertising efforts in-house, where we have improved efficiencies from six thousand digital impressions per month to 1.7 million impressions with a 3-5% engagement rate in the month of December 2016 alone.

Our optimization curve on our digital ad placement platform is still being tweaked and our access to this digital marketing technology will give us the ability to increase to approximately 5-6 million viewers per month within the next 30-45 days. Our platform gives us, Big Data access, such as Nielson, whose technology allows us to target an audience who is looking for health insurance at the time the consumer is in a buying mode. In addition we have implemented a “Beaconing” technology, which allows us to create a beacon over certain locations (within 5 meters of an address) targeting the consumers location through their mobile device. Then once the consumer returns to their location of business or residence their WIFI will pick up that data and create a cross device digitization for re-targeting purposes. This technology can target consumers that visit every dispensary, every MMJ venue within our geo-demographic region. This is known as conquest marketing, to reach the consumers based on behavior, location and the most impressive, targeting consumers that have visited these locations as far back as 1 year.